Safety and Tolerability of SYNB1020-CP-001

Summary

A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics

Timeline

Start

2017-06-16

Primary completion

2017-11-02

Completion

2018-04-11

Drugs

Indications